Journal
CANCER CELL
Volume 40, Issue 5, Pages 441-443Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2022.03.013
Keywords
-
Categories
Funding
- National Cancer Institute (NCI) [R01 CA244899, CA252222]
- Amgen
- Celgene/BMS
- Karyopharm
- NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract [75N93019C00051]
- NIAID Center of Excellence for Influenza Research and Surveillance (CEIRS) [HHSN272201400008C, HHSN272201400006C]
- NIAID [U01AI141990, U01AI150747]
- JPBFoundation
- Open Philanthropy Project [2020-215611 [5384]]
- Serological Sciences Network (SeroNet) in partwith federal funds fromthe National Cancer Institute, National Institutes of Health [75N91019D00024, 75N91021F00001]
- Price Family Foundation (SCA)
- Einstein-Rockefeller-CUNY Center for AIDS Research [P30AI124414]
- Albert Einstein Cancer Center [P30CA013330]
- Center of Excellence for Multiple Myeloma Philantropy